Physician

Indu Sharma, M.D.

According to 2025 Medicare claims, Indu Sharma, M.D. (NPI: 1386793313) practices hematology/oncology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Bergen, NJ. This provider's primary affiliated billing organization is CARDIOLOGY & ONCOLOGY ASSOC., P.A. (NPI: 1881865046; TIN: 223144262) and primary practice location at 07430-3517.

Sharma's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 627 traditional Medicare patients, billed 198,763 HCPCS/CPT codes, and received $3,209,207 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,439 prescription claims across 312 beneficiaries totaling $4,871,919 in drug costs, led by Revlimid (Lenalidomide). DME data shows 137 claims. Open Payments data shows 78 records totaling $1,537. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,588,878 to $4,871,919. In contrast, DME billing represents a smaller volume and moved from a higher plateau to a lower plateau, from $18,516 to $7,893.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	709	289,166	$3,360,101
2016	738	340,123	$3,720,646
2017	701	326,940	$3,355,959
2018	723	262,431	$3,684,424
2019	647	288,517	$3,668,556
2020	645	279,645	$4,024,606
2021	595	281,933	$4,280,090
2022	609	223,750	$3,213,920
2023	609	186,013	$2,805,417
2024	627	198,763	$3,209,207

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	272	2,257	$1,588,878
2016	275	2,255	$1,609,123
2017	277	2,172	$1,764,493
2018	285	2,370	$2,583,179
2019	302	2,599	$2,985,945
2020	292	2,677	$3,151,888
2021	284	2,203	$2,686,320
2022	277	2,171	$3,690,996
2023	274	1,929	$3,675,465
2024	312	2,439	$4,871,919

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	385	$63,171
2016	N/R	363	$37,601
2017	N/R	164	$6,657
2018	N/R	126	$5,272
2019	N/R	137	$8,797
2020	N/R	233	$13,758
2021	N/R	258	$9,557
2022	N/R	147	$6,059
2023	N/R	26	$1,320
2024	N/R	137	$7,592

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	368	1,282	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	307	1,813	$72
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	189	1,575	$63
36415	Insertion of needle into vein for collection of blood sample	475	2,915	$9
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	472	2,908	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	93	2,604	$1,740,295
Imbruvica	Ibrutinib	26	780	$470,804
Fotivda	Tivozanib Hcl	13	364	$401,549
Jakafi	Ruxolitinib Phosphate	12	360	$202,963
Keytruda	Pembrolizumab	17	357	$197,855

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	16	$3,858
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	35	$1,273
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	15	$1,089
J9190	Injection, fluorouracil, 500 mg	N	N/R	36	$701
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	35	$671

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$1,537	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Indu Sharma, M.D.?

Tedicare shows public-source Medicare data for Indu Sharma, M.D. (NPI 1386793313), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Indu Sharma, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Indu Sharma, M.D.?

Indu Sharma, M.D. is linked to CARDIOLOGY & ONCOLOGY ASSOC., P.A. (billing NPI 1881865046) in the available physician profile data.

Does Indu Sharma, M.D. have Open Payments data?

Indu Sharma, M.D. has 78 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.